ArticleDiscover oncology2025
The role of LAMA5 in breast cancer progression and its potential in immunotherapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLaminin alpha-5 (LAMA5), a major extracellular matrix component, is involved in tumor progression by modulating cell adhesion, migration, and tissue architecture. However, its specific role in breast cancer (BRCA) remains unclear.
methodsWe analyzed LAMA5 expression in BRCA and normal tissues using TCGA and GTEx datasets. Differential expression analysis was conducted using DESeq2. Survival associations were assessed using Kaplan-Meier and Cox regression models. GSEA was performed to identify LAMA5-related biological pathways. Immune infiltration was evaluated using CIBERSORT and ESTIMATE algorithms. Single-cell RNA sequencing and spatial transcriptomics were used to explore the spatial distribution and cellular localization of LAMA5. Drug sensitivity and immunotherapy response analyses were also conducted.
resultsLAMA5 was significantly downregulated in BRCA tissues compared to normal tissues. Higher LAMA5 expression was associated with better recurrence-free and overall survival. Functional enrichment analysis revealed that LAMA5 is involved in immune regulation and extracellular matrix-related pathways. Single-cell RNA sequencing and spatial transcriptomics demonstrated spatial and cellular heterogeneity of LAMA5 expression in BRCA. Immune-related analyses suggested that LAMA5 may influence immune cell infiltration and contribute to immune microenvironment remodeling. ROC analysis indicated moderate predictive value for immunotherapy response (AUC = 0.704), and LAMA5 expression was positively associated with sensitivity to chemotherapeutic agents including cisplatin and docetaxel.
conclusionLAMA5 is a potential prognostic biomarker in BRCA and may play a dual role in modulating tumor progression and immune responses. Its association with drug sensitivity and immunotherapy outcomes highlights its value as a potential therapeutic target in precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.